Determination of captopril in pharmaceutical preparation and biological fluids using two- and three-way chemometrics methods

Spectrophotometric method has been developed for the direct quantitative determination of captopril in pharmaceuticalpreparation and biological fluids(human plasma and urine)samples.The method was accomplished based on parallel factoranalysis(PARAFAC)and partial least squares(PLS).The study was carried out in the pH range from 2.0 to 12.8 and with aconcentration from 0.70 to 61.50 μg mL~(-1)of captopril.Multivariate calibration models such as PLS at various pH and PARAFACwere elaborated from ultraviolet spectra deconvolution and captopril determination.The best models for this system were obtainedwith PARAFAC and PLS at pH 2.0.The applications of the method for determination of real samples were evaluated by analysis ofcaptopril in pharmaceutical preparations and biological fluids with satisfactory results.The accuracy of the method,evaluatedthrough the RMSEP,was 0.5801 for captopril with best calibration curve by PARAFAC and 0.6168 for captopril with PLS at pH 2.0model.     

Two- and three-way chemometrics methods applied for spectrophotometric determination of lorazepam in pharmaceutical formulations and biological fluids

In this work, direct determination of lorazepam, an anxiolytic and sedative agent, in pharmaceutical formulations and biological fluids (urine and human plasma) was accomplished based on ultraviolet spectrophotometry (260-380 nm) using parallel factor analysis (PARAFAC) and partial least squares (PLS). The study was carried out in the pH range from 1.0 to 12.0 and with a concentration range from 0.50 to 8.75 μg ml⁻¹ of lorazepam. Multivariate calibration models using PLS at different pH and PARAFAC were elaborated for ultraviolet spectra deconvolution and lorazepam quantitation. The best models for the system were obtained with PARAFAC and PLS at pH = 2.05 (PLS-PH2). The capabilities of the method for the analysis of real samples were evaluated by determination of lorazepam in pharmaceutical preparations and biological (urine and plasma) fluids with satisfactory results. The accuracy of the method, evaluated through the root mean square error of prediction (RMSEP), was 0.0429 for lorazepam with best calibration curve by PARAFAC and 0.0467 for lorazepam with PLS model at best pH. The protolytic equilibria of lorazepam at 25 °C and ionic strength of 0.1 M have also been determined spectrophotometrically. Protolytic equilibria of lorazepam were evaluated by DATAN program using the corresponding absorption spectra-pH data. The obtained pK_a values of lorazepam are 1.54 and 11.61 for pK_a1 and pK_a2, respectively.     

PARAFAC and PLS applied to spectrophotometric determination of tetracycline in pharmaceutical formulation and biological fluids

A simple and rapid analytical procedure was proposed for determination of tetracycline in pharmaceutical formulation, urine and plasma based on chemometrics methods and spectrophotometric measurements. The calibration set was constructed with twenty solutions in concentration range 0.25-13.00 microg ml(-1) for tetracycline. The procedure was repeated at nine different pH values. Partial least squares (PLS) models were built at each pH and used to determinate a set of synthetic tetracycline solutions. The best model was obtained at pH 8.00 (PLS-PH8). Parallel factor analysis (PARAFAC) model was applied to a three-way array constructed using all the pH data sets and enabled better results. The capabilities of the method for the analysis of real samples were evaluated by determination of tetracycline in pharmaceutical formulations and biological fluids with satisfactory results.     

Spectrofluorometric determination of ketorolac tromethamine via its oxidation with cerium(IV) in pharmaceutical preparations and biological fluids

A simple and sensitive fluorometric method for determination of ketorolac tromethamine was studied. The method depends on oxidation of the drug with cerium(IV) and subsequent monitoring of the fluorescence of the induced cerium(III) at lambda(em) 365 nm after excitation at 255 nm. Different variables affecting the reaction conditions, such as the concentrations of cerium(IV), sulfuric acid concentration, reaction time, and temperature, were carefully studied and optimized. Under the optimum conditions, a linear relationship was found between the relative fluorescence intensity and the concentration of the investigated drug in the range of 0.1-0.8 microg/mL. No interferences could be observed from the excipients commonly present in dosage forms. The proposed method was successfully applied to the analysis of the investigated drug in its pure form, pharmaceutical preparations, and biological fluids with good accuracy and precision. The recoveries for pharmaceutical formulations ranged from 99.8-101.0 +/- 0.6% for tablets, 98.5-101.0 +/- 1.0% for ampoules, and 99.0-100.5 +/- 0.7% for eye drops. The results obtained by the proposed method were satisfactory compared with those obtained by the official method. The recoveries for biological fluids were 99.1-100.4 +/- 0.7 and 99.0-100.0 +/- 0.5% for plasma and urine, respectively.     

Spectrofluorometric determination of verapamil hydrochloride in pharmaceutical preparations and human plasma using organized media: application to stability studies

A highly sensitive spectrofluorometric method was developed for the determination of verapamil hydrochloride (VP HCl) in pharmaceutical formulations and biological fluids. The proposed method is based on investigation of the fluorescence spectral behavior of VP HCl in micellar systems, such as sodium dodecyl sulfate (SDS) and beta-cyclodextrin (beta-CD). In aqueous solutions of borate buffer of pH 9 and 8.5, VP HCI was well incorporated into SDS and beta-CD, respectively, with enhancement of its native fluorescence. The fluorescence was measured at 318 nm after excitation at 231 nm. The fluorescence intensity enhancements were 183 and 107% in SDS and in beta-CD, respectively. The fluorescence-concentration plots were rectilinear over the range of 0.02-0.2 and 0.02-0.25 microg/mL, with lower detection limits of 5.58 x 10(-3) and 3.62 x 10(-3) microg/mL in SDS and beta-CD, respectively. The method was successfully applied to the analysis of commercial tablets and the results were in good agreement with those obtained with the official method. The method was further applied to the determination of VP HCl in real and spiked human plasma. The mean % recoveries in the case of spiked human plasma (n=4) was 92.59 +/- 3.11 and 88.35 +/- 2.55 using SDS and beta-CD, respectively, while that in real human plasma (n=3) was 90.17 +/- 6.93 and 89.17 +/- 6.50 using SDS and beta-CD, respectively. The application of the method was extended to the stability studies of VP HCl after exposure to ultraviolet radiation and upon oxidation with hydrogen peroxide.     

First- and second-order multivariate calibration applied to biological samples: determination of anti-inflammatories in serum and urine

First- and second-order multivariate calibration of fluorescence data have been compared as regards the determination of anti-inflammatories and metabolites in the biological fluids serum and urine. The simultaneous resolution of naproxen-salicylic acid mixtures in serum and naproxen-salicylic acid-salicyluric acid mixtures in urine was accomplished and employed for a discussion of the relative advantages of the applied chemometric tools. The analysis of second-order fluorescence excitation-emission matrices was performed using iteratively reweighted generalized rank annihilation method (IRGRAM), parallel factor analysis (PARAFAC), and self-weighted alternating trilinear decomposition (SWATLD). The results were compared with first-order fluorescence emission data analyzed with partial least-squares regression (PLS). In all cases, the performance of the methods was improved through the formation of inclusion complexes of the analytes with beta-cyclodextrin. The concentration ranges in which the analytes could be determined were as follows: naproxen, 0-250 ng mL(-1) in serum and 0-200 ng mL(-1) in urine; salicylic acid, 0-500 ng mL(-1) in serum and 0-300 ng mL(-1) in urine, and salicyluric acid, 0-300 ng mL(-1) in urine.     

Determination of the antiplatelet agent. KB-3022, and its metabolite by high-performance liquid chromatography

A rapid, accurate and reproducible high-performance liquid chromatographic method for the simultaneous determination of a new antiplatelet agent, ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-ylacetate (KB-3022), and its main metabolite, 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-ylacetic acid (desethyl KB-3022), in biological fluids has been developed. KB-3022 and desethyl KB-3022 in plasma or urine were extracted with a mixture of n-hexane and dichloromethane (1:1), separated on a reversed-phase C18 column with a mixture of 0.01 M (NH4)2HPO4 (pH 3.0), acetonitrile and isopropyl alcohol as a mobile phase, and quantitated by ultraviolet absorbance measurement at 340 nm. 4-[2-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)pyrrol-1-yl]butyric acid was used as an internal standard. The detection limit of KB-3022 in plasma was 3 ng/ml, and that of KB-3022 in urine and desethyl KB-3022 in plasma or urine was 1 ng/ml. The coefficients of variation for the determination of KB-3022 or desethyl KB-3022 in plasma or urine were below 5.6%. This method was applied to the determination of the plasma concentration of KB-3022 and desethyl KB-3022 after intravenous administration to rats.     

Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography

A high-performance liquid chromatographic method has been developed which enables sensitive determination of captopril and its mixed disulphides in plasma and urine after oral administration of a new antihypertensive agent, 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (DU-1219, I). Captopril is derivatized with a new reagent, N-(4-benzoylphenyl)maleimide and the derivative is extracted with chloroform and assayed using a liquid chromatograph equipped with an ultraviolet detector at 254 nm. Mixed disulphides of captopril with thiol compounds such as cysteine, glutathione and plasma proteins are reduced with tributylphosphine to form captopril, followed by derivatization with N-(4-benzoylphenyl)maleimide. Accurate determinations are possible over a concentration range of 10-500 ng/ml captopril in plasma, and 100-2500 ng/ml captopril in urine. The coefficients of variation of captopril in plasma (200 ng/ml) and urine (500 ng/ml) are 3.7% and 2.6%, respectively, and those of mixed disulphides of captopril are similar to those of captopril. Plasma levels and urinary excretion of captopril and its mixed disulphides in healthy volunteers following single oral administration of I (50 mg) have also been determined.     

Spectrofluorometric determination of fluvoxamine in dosage forms, spiked plasma, and real human plasma by derivatization with fluorescamine

A sensitive, simple, and selective spectrofluorometric method was developed for the determination of fluvoxamine (FXM) in pharmaceutical formulations and biological fluids. The method is based upon the reaction between the drug and fluorescamine in borate buffer of pH 8.0 to yield a highly fluorescent derivative that is measured at 481 nm after excitation at 383 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized. The method was applied for the determination of the drug over the concentration range of 0.1-1.1 microg/mL with a detection limit of 0.01 microg/mL (2 x 10(-8) M). The proposed method was successfully applied to the analysis of commercial tablets. The results obtained were in good agreement with those obtained using a reported spectrophotometric method. The method was applied for the determination of FXM in spiked human plasma with recovery (n=4) of 97.32 +/- 1.23%, while that in real human plasma (n=3) was 90.79 +/- 2.73%. A proposal for the reaction pathway is presented.     

Determination of benzoic acid and hippuric acid in human plasma and urine by high-performance liquid chromatography

For patients with inborn errors of urea synthesis, oral administration of sodium benzoate is the usual treatment to increase the nitrogen excretion. Thus, monitoring hippuric acid and benzoic acid simultaneously in human biological fluids is considered to be clinically important. We developed a simple and accurate high-performance liquid chromatographic method for the simultaneous determination of hippuric acid and benzoic acid in human plasma and urine. This method requires no extraction step. Aliquots of urine and plasma are added to a solution of internal standard (o-chlorobenzoic acid) in acetonitrile and directly injected onto a reversed-phase column using an acidic (pH 2.7) eluent and ultraviolet detection at 235 nm. The preliminary plasma concentration-time and urinary excretion rate-time profiles of hippuric acid and benzoic acid from a healthy subject receiving small, medium and large doses of sodium benzoate are reported.     

Multivariate methods on the excitation emission matrix fluorescence spectroscopic data of diesel-kerosene mixtures: a comparative study

Quantitative determination of kerosene fraction present in diesel has been carried out based on excitation emission matrix fluorescence (EEMF) along with parallel factor analysis (PARAFAC) and N-way partial least squares regression (N-PLS). EEMF is a simple, sensitive and nondestructive method suitable for the analysis of multifluorophoric mixtures. Calibration models consisting of varying compositions of diesel and kerosene were constructed and their validation was carried out using leave-one-out cross validation method. The accuracy of the model was evaluated through the root mean square error of prediction (RMSEP) for the PARAFAC, N-PLS and unfold PLS methods. N-PLS was found to be a better method compared to PARAFAC and unfold PLS method because of its low RMSEP values.     

Spectrophotometric determination of four macrolide antibiotics in pharmaceutical formulations and biological fluids via binary complex formation with eosin [corrected

A simple, rapid, and sensitive validated spectrophotometric method was developed for the determination of certain macrolide antibiotics namely, erythromycin (I), azithromycin dihydrate (II), clarithromycin (III), and roxithromycin (IV) in bulk powders, pharmaceutical formulations, and spiked biological fluids. The proposed method is based on the formation of a binary complex between each of the studied drugs and eosin Y in aqueous buffered medium. Under the optimum conditions, the binary complexes showed absorption maxima at 542-544 nm. The absorbance of the binary complexes obeyed Beer's law over the concentration range of 1-10 micro/g/mL for II, 2-20 microg/mL for I and IV, and 3-30 microg/mL for III. The mean percentage recoveries were 100.04 +/- 0.83, 99.98 +/- 0.80, 100.17 +/- 0.91, and 99.55 +/- 0.91, with minimum detectable molarities of 2 x 10(-7) for I and II, 4 x 10(-7) for III, and 3 x 10(-7) for IV. The different experimental parameters affecting the development and stability of the colors were studied and optimized. The proposed method was successfully applied to the analysis of the cited drugs in some pharmaceutical formulations. The results obtained were in good agreement with those obtained using the reference methods. The proposed method was further applied to spiked human urine and plasma. A proposal of the reaction pathway is suggested.     

Cathodic adsorptive stripping voltammetric determination of nalidixic acid in pharmaceuticals, human urine and serum

The quinolone antibacterial agent nalidixic acid (NAL) was studied by cyclic voltammetry (CV) and cathodic adsorptive stripping voltammetry (CASV). A sensitive method is described for the determination of NAL in its pure form, dosage forms and biological fluids. Controlled adsorptive accumulation of NAL on a hanging mercury drop electrode provides the basis for the direct stripping measurement of that compound in the nanomolar concentration level. Different variables were studied and optimized. The proposed method depends upon the voltammetric activity of NAL in Britton-Robinson buffer, whereby a well-defined cathodic peak is produced at pH 5.0 in presence of NO(3)(-). The calibration graph to determine NAL was linear in the range 7.4x10(-8)-2.5x10(-5) M by CASV. CAS voltammetry has been proved to be advantageous over a liquid chromatographic (LC) technique, allowing to detection limit signal to noise ratio, (s/n=3) of 0.766 ng ml(-1) (3.3x10(-9) M) NAL to be reached. The relative standard deviation (n=5) was 5.2% at concentration level of 1.0x10(-7) M NAL. The degree of interference from coexisting metal ions on the CASV signal for NAL was evaluated. The method was applied to two different commercial pharmaceutical products (Negram tablets and suspension) with very good recoveries. It was also shown that the method was successfully applied to the determination of NAL in human urine and blood serum. Mean recoveries were 98.8+/-0.3 and 98.9+/-0.41%, respectively.     

Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids

Methods reported previously for the determination of encainide and its metabolites in biological fluids have not been extensively described and evaluated. We report an improved high-performance liquid chromatographic assay for the quantification of these compounds in plasma and urine with complete estimation of the accuracy and reproducibility of the analytical method. The major improvements consist of: (1) the use of ethaverine as an appropriate internal standard; (2) the use of the salting-out technique which improves the extraction recovery for the metabolites of encainide and the sensitivity of the assay; and (3) a shift of the ultraviolet absorption wavelength from 254 to 270 nm to increase the selectivity of the detection.     

Determination of Trace Amounts of Lorazepam by Adsorptive Cathodic Differential Pulse Stripping Method in Pharmaceutical Formulations and Biological Fluids

Abstract

A new adsorptive cathodic differential pulse stripping voltammetry method for the direct determination of lorazepam at trace levels in pharmaceutical formulations and biological fluids is proposed. The procedure involves an adsorptive accumulation of lorazepam on a hanging mercury drop electrode (HMDE), followed by reduction of adsorbed lorazepam by voltammetric scan using differential pulse modulation. The optimum conditions for the analysis of lorazepam are pH=2 using Britton‐Robinson (B‐R) buffer, accumulation potential of ?0.2 V (vs. Ag/AgCl), and accumulation time of 40 sec. The peak current is proportional to the concentration of lorazepam, and a linear calibration graph is obtained at 0.05–1.15 µg mL^?1. A relative standard deviation of 2.41% (n=3) was obtained, and the limit of detection was 0.019 µg mL^?1. The capability of the method for the analysis of real samples was evaluated by determination of lorazepam in pharmaceutical preparations and biological (urine and plasma) fluids with satisfactory results.     

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method.

A rapid, selective and reproducible high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the determination of the anti-cancer agent Taxotere in biological fluids. The method involves a solid-phase extraction step (C2 ethyl microcolumns) using a Varian Advanced Automated Sample Processor (AASP) followed by reversed-phase HPLC. The validated quantitation range of the method is 10-2500 ng/ml in plasma with coefficients of variation < or = 11%. The method is also suitable for the determination of Taxotere in urine samples under the same conditions. The method was applied in a phase I tolerance study of Taxotere in cancer patients, allowing the pharmacokinetic profile of Taxotere to be established.     

High-performance liquid chromatographic separation of cadralazine from its potential metabolites and degradation products. Quantitation of the drug in human plasma and urine

The chromatographic behaviour of cadralazine and its potential metabolites and degradation products with respect to pH, buffer molarity and composition of eluent is described. A selective method with an adequate sensitivity for the determination of the drug in human plasma and urine is also reported. The method includes extraction of biological fluids with chloroform and the analysis of extracts on a reversed-phase column with isocratic elution and detection at 254 nm. The method has been applied to the analysis of plasma and urine of a patient administered a single oral dose of 30 mg of cadralazine.     

Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography

A reversed-phase column liquid chromatographic method for the determination of remoxipride, a novel antipsychotic drug, in biological fluids is described. A simple one-step extraction is used followed by liquid chromatography on a 3-microns octadecylsilica column and ultraviolet absorbance detection. The method is accurate and precise for clinical remoxipride levels in both plasma and urine. For situations where a higher sensitivity is necessary a two-step extraction and a modified mobile phase are used. With this modification plasma concentrations down to 2 nM can be determined with acceptable precision.     

Highly sensitive fluorescence quantification of irinotecan in biological fluids with the aid of second-order advantage

<正>A rapid,green and highly sensitive excitation-emission matrix(EEM) fluorescence method was proposed for analysis of irinotecan(CPT-11) in biological fluids including human plasma and urine samples of uncalibrated interferences with the aid of second-order advantage.Due to the serious spectral overlapping from biological matrices,the parallel factor analysis(PARAFAC) and the alternating normalization-weighted error(ANWE) have been recommended to perform directly calibration and overcome the problem which makes the traditional fluorospectrophotometer in trouble.Satisfactory results can be achieved.Furthermore, performance of the proposed method was evaluated based on figures of merit and some statistical parameters.The accuracy of both algorithms was validated by the elliptical joint confidence region(EJCR) test.The precision and repeatability were also investigated by the relative standard deviations(RSDs) of intra-day and inter-day.     

Chemometrics assisted spectrophotometric determination of pyridine in water and wastewater

The paper reports a direct method for the determination of pyridine in water and wastewater samples based on ultraviolet spectrophotometric measurements using multi-way modeling techniques. Parallel factor analysis (PARAFAC) and multi-way partial least squares (N-PLS) regression methods were employed for the decomposition of spectra and quantification of pyridine. The study was carried out in the pH range of 1.0-12.0 and concentration range of 0.67-51.7 μg mL⁻¹ of pyridine. Both the three-way PARAFAC and tri-PLS1 models successfully predicted the concentration of pyridine in synthetic (spiked) river water and field wastewater samples. The mean recovery obtained from PARAFAC regression model were 97.39% for the spiked and 99.84% for the field wastewater samples, respectively. The sensitivity and precision of the method for pyridine determination were 0.58% and 5.95%, respectively. The N-PLS regression model yielded mean recoveries of 99.29% and 100.18% for the spiked and field wastewater samples, respectively. The prediction accuracy of the methods was evaluated through the root mean square error of prediction (RMSEP). For PARAFAC, it was 0.65 and 0.82 μg mL⁻¹ for spiked river water and field wastewater samples, respectively, while for N-PLS, it was 0.25 and 0.37 μg mL⁻¹, respectively. Both the PARAFAC and N-PLS methods, thus, yielded satisfactory results for the prediction of pyridine concentration in water and wastewater samples.